The medical device CRO market is projected to grow at an annualized rate of 6.4%, till 2030
Roots Analysis has done a detailed study on “Medical Device CRO Market (2nd Edition), 2020-2030”. covering various importantaspects of the industry and identifying key future growth opportunities.
To order this 400+ page report, which features 240+figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html
KeyMarket Insights
§ Since 2015, over7,500 medical device focused clinical trials, involving the participation ofclose to 2.9 million patients across different hospitals / medical centers,have been registered worldwide
§ Over 300 CROspresently claim to possess the necessary capabilities to offer a wide range ofpreclinical and clinical research-related services to medical device-focusedbusiness entities
§ The market landscapeis highly fragmented, featuring the presence of both established players andnew entrants; majority of such firms are located in the developed geographies
§ Owing to the highcompetition in this field, stakeholders are steadily expanding theircapabilities in order to augment their respective service portfolios and alsocomply to evolving industry benchmarks
§ Over the years, thedomain has witnessed an increase in merger and acquisition activity, with manyCROs expanding their presence across multiple geographies and growing theirrespective service portfolios
§ Several companies inthis domain have established strong brand positions across different regions;in future, such companies are anticipated to contribute the most to the overallrevenue generation potential
§ Driven by the growingdemand for effective treatment modalities across various therapeutic areas, themarket is poised to witness sustained growth across various device classes andgeographies
§ In the long term, weexpect the market to reach over USD 15 billion; the current and futureopportunity is likely to be distributed across companies of different sizesoffering various types of clinical and preclinical services
Formore information,please visit https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html
Table of Contents
1. PREFACE
1.1. Scopeof the Report
1.2. ResearchMethodology
1.3. ChapterOutlines
2. EXECUTIVESUMMARY
3. INTRODUCTION
3.1. ChapterOverview
3.2. Overviewof Medical Devices
3.2.1. HistoricalEvolution of Medical Devices
3.2.2. Classificationof Medical Devices
3.3. Overviewof Contract Research Organizations (CROs)
3.3.1. Evolutionof CROs
3.4. Roleof CROs in the Medical Device Industry
3.5. Typesof Medical Device CROs
3.6. Typesof Services Offered by CROs
3.7. Advantagesof Outsourcing Operations to CROs
3.8. Risksand Challenges Associated with Outsourcing
3.9. KeyConsiderations for Selecting a Suitable CRO Partner
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Medical Device CROs: Clinical Service Providers
4.2.1. Analysisby Year of Establishment
4.2.2. Analysisby Company Size
4.2.3. Analysisby Location of Headquarters
4.2.4. Analysisby Company Size and Location of Headquarters
4.2.5. Analysisby Area of Specialization
4.2.6. Analysisby Device Class
4.2.7. Analysisby Type of Clinical Operation Services Offered
4.2.8. Analysisby Type of Regulatory Affairs-related Services Offered
4.2.9. Analysisby Type of Additional Services Offered
4.2.10. Analysisby Medical Device Regulatory Compliance Authorities
4.3. Medical Device CROs: Preclinical Service Providers
4.3.1. Analysisby Year of Establishment
4.3.2. Analysisby Company Size
4.3.3. Analysisby Location of Headquarters
4.3.4. Analysisby Company Size and Location of Headquarters
4.3.5. Analysisby Type of Preclinical Services Offered
4.4. Medical Device CROs: Standalone Service Providers
4.4.1. Analysisby Year of Establishment
4.4.2. Analysisby Company Size
4.4.3. Analysisby Location of Headquarters
4.4.4. Analysisby Company Size and Location of Headquarters
5. REGULATORYAND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
5.1. ChapterOverview
5.2. GeneralRegulatory and Reimbursement Guidelines for Medical Devices
5.3. Regulatoryand Reimbursement Landscape in North America
5.3.1. TheUS Scenario
5.3.1.1. Regulatory Authority
5.3.1.2. Review / Approval Process
5.3.1.3. Reimbursement Landscape
5.3.1.3.1. PayerMix
5.3.1.3.2. ReimbursementProcess
5.3.2. TheCanadian Scenario
5.3.2.1. Regulatory Authority
5.3.2.2. Review / Approval Process
5.3.2.3. Reimbursement Landscape
5.3.2.3.1. PayerMix
5.3.2.3.2. ReimbursementProcess
5.3.3. TheMexican Scenario
5.3.3.1. Regulatory Authority
5.3.3.2. Review / Approval Process
5.3.3.3. Reimbursement Landscape
5.3.3.3.1. PayerMix
5.4. Regulatoryand Reimbursement Landscape in Europe
5.4.1. OverallScenario
5.4.1.1. Overall Regulatory Authority
5.4.1.2. Overall Review / Approval Process
5.4.2. TheUK Scenario
5.4.2.1. Regulatory Authority
5.4.2.2. Review / Approval Process
5.4.2.3. Reimbursement Landscape
5.4.2.3.1. PayerMix
5.4.2.3.2. ReimbursementProcess
5.4.3. TheFrench Scenario
5.4.3.1. Regulatory Authority
5.4.3.2. Review / Approval Process
5.4.3.3. Reimbursement Landscape
5.4.3.3.1. PayerMix
5.4.3.3.2. ReimbursementProcess
5.4.4. TheGerman Scenario
5.4.4.1. Regulatory Authority
5.4.4.2. Review / Approval Process
5.4.4.3. Reimbursement Landscape
5.4.4.3.1. PayerMix
5.4.4.3.2. ReimbursementProcess
5.4.5. TheItalian Scenario
5.4.5.1. Regulatory Authority
5.4.5.2. Review / Approval Process
5.4.5.3. Reimbursement Landscape
5.4.5.3.1. PayerMix
5.4.5.3.2. ReimbursementProcess
5.4.6. TheSpanish Scenario
5.4.6.1. Regulatory Authority
5.4.6.2. Review / Approval Process
5.4.6.3. Reimbursement Landscape
5.4.6.3.1. PayerMix
5.4.6.3.2. ReimbursementProcess
5.5. Regulatoryand Reimbursement Landscape in Asia-Pacific and Rest of the World
5.5.1. TheAustralian Scenario
5.5.1.1. Regulatory Authority
5.5.1.2. Review / Approval Process
5.5.1.3. Reimbursement Landscape
5.5.1.3.1. PayerMix
5.5.1.3.2. ReimbursementProcess
5.5.2. TheBrazilian Scenario
5.5.2.1. Regulatory Authority
5.5.2.2. Review / Approval Process
5.5.2.3. Reimbursement Landscape
5.5.2.3.1. PayerMix
5.5.2.3.2. ReimbursementProcess
5.5.3. TheChinese Scenario
5.5.3.1. Regulatory Authority
5.5.3.2. Review / Approval Process
5.5.3.3. Reimbursement Landscape
5.5.3.3.1. PayerMix
5.5.3.3.2. ReimbursementProcess
5.5.4. TheIndian Scenario
5.5.4.1. Regulatory Authority
5.5.4.2. Review / Approval Process
5.5.4.3. Reimbursement Landscape
5.5.4.3.1. PayerMix
5.5.5. TheIsraeli Scenario
5.5.5.1. Regulatory Authority
5.5.5.2. Review / Approval Process
5.5.5.3. Reimbursement Landscape
5.5.5.3.1. PayerMix
5.5.6. TheJapanese Scenario
5.5.6.1. Regulatory Authority
5.5.6.2. Review / Approval Process
5.5.6.3. Reimbursement Landscape
5.5.6.3.1. PayerMix
5.5.6.3.2. ReimbursementProcess
5.5.7. TheNew Zealand Scenario
5.5.7.1. Regulatory Authority
5.5.7.2. Review / Approval Process
5.5.7.3. Reimbursement Landscape
5.5.7.3.1. PayerMix
5.5.7.3.2. ReimbursementProcess
5.5.8. TheSingapore Scenario
5.5.8.1. Regulatory Authority
5.5.8.2. Review / Approval Process
5.5.8.3. Reimbursement Landscape
5.5.8.3.1. PayerMix
5.5.8.3.2. ReimbursementProcess
5.5.9. TheSouth Korean Scenario
5.5.9.1. Regulatory Authority
5.5.9.2. Review / Approval Process
5.5.9.3. Reimbursement Landscape
5.5.9.3.1. PayerMix
5.5.9.3.2. ReimbursementProcess
5.5.10. TheSouth African Scenario
5.5.10.1. RegulatoryAuthority
5.5.10.2. Review/ Approval Process
5.5.10.3. ReimbursementLandscape
5.5.11. TheTaiwan Scenario
5.5.11.1. RegulatoryAuthority
5.5.11.2. Review/ Approval Process
5.5.11.3. ReimbursementLandscape
5.5.11.3.1. PayerMix
5.5.11.3.2. ReimbursementProcess
5.5.12. TheThailand Scenario
5.5.12.1. RegulatoryAuthority
5.5.12.2. Review/ Approval Process
5.5.12.3. ReimbursementLandscape
5.6. Comparisonof Regional Regulatory Control
5.7. ConcludingRemarks
6. COMPANYPROFILES
6.1. ChapterOverview
6.2. Avania(Formerly known as Factory CRO)
6.2.1. CompanyOverview
6.2.2. Service Portfolio
6.2.3. FutureOutlook
6.3. CharlesRiver Laboratories
6.3.1. CompanyOverview
6.3.2. ServicePortfolio
6.3.3. FutureOutlook
6.4. Clinlogix
6.4.1. CompanyOverview
6.4.2. ServicePortfolio
6.4.3. FutureOutlook
6.5. CROMSOURCE
6.5.1. CompanyOverview
6.5.2. ServicePortfolio
6.5.3. FutureOutlook
6.6. CSSiLifeSciences
6.6.1. CompanyOverview
6.6.2. ServicePortfolio
6.6.3. FutureOutlook
6.7. EurofinsMedical device Testing
6.7.1. CompanyOverview
6.7.2. ServicePortfolio
6.7.3. FutureOutlook
6.8. genae
6.8.1. CompanyOverview
6.8.2. ServicePortfolio
6.8.3. FutureOutlook
6.9. IMARCResearch
6.9.1. CompanyOverview
6.9.2. ServicePortfolio
6.9.3. FutureOutlook
6.10. IQVIA
6.10.1. CompanyOverview
6.10.2. ServicePortfolio
6.10.3. FutureOutlook
6.11. Medpace
6.11.1. CompanyOverview
6.11.2. ServicePortfolio
6.11.3. FutureOutlook
6.12. NAMSA
6.12.1. CompanyOverview
6.12.2. ServicePortfolio
6.12.3. FutureOutlook
6.13. QserveGroup
6.13.1. CompanyOverview
6.13.2. ServicePortfolio
6.13.3. FutureOutlook
6.14. Regulatoryand Clinical Research Institute (Now a part of Covance)
6.14.1. CompanyOverview
6.14.2. ServicePortfolio
6.14.3. FutureOutlook
6.15. WuXiAppTec
6.15.1. CompanyOverview
6.15.2. ServicePortfolio
6.15.3. FutureOutlook
7. MEDICALDEVICE DEVELOPER AND CRO RELATIONSHIPS: KEY VALUE DRIVERS AND PERFORMANCE INDICATORS
7.1. ChapterOverview
7.2. Definitionand Importance of Key Performance Indicators (KPIs)
7.3. KeyConsiderations for Selection of KPIs
7.4. Typesof KPIs
7.4.1. FinancialIndicators
7.4.1.1. MostImportant KPIs
7.4.1.1.1. FinancialStability
7.4.1.1.2. Costof Services Offered
7.4.1.1.3. ComparativeAnalysis of Financial Indicators
7.4.1.2. IndustryPerspective
7.4.1.2.1. Sponsors’(Big Pharma) Perspective
7.4.1.2.2. ContractService Providers’ Perspective
7.4.2. Processand Capability Indicators
7.4.2.1. MostImportant KPIs
7.4.2.1.1. Proximityto Sponsor
7.4.2.1.2. Capabilityto Innovate / Mitigate Risk
7.4.2.1.3. Strengthof Service Portfolio
7.4.2.1.4. ComparativeAnalysis of Process / Capability Indicators
7.4.2.2. IndustryPerspective
7.4.2.2.1. Sponsors’(Big Pharma) Perspective
7.4.2.2.2. ContractService Providers’ Perspective
7.4.3. MarketReputation Indicators
7.4.3.1. MostImportant KPIs
7.4.3.1.1. Flexibility/ Adaptability
7.4.3.1.2. TimeManagement
7.4.3.1.3. Quality/ Reliability
7.4.3.1.4. RegulatoryCompliance / Track Record
7.4.3.1.5. ComparativeAnalysis of Market Reputation Indicators
7.4.3.2. IndustryPerspective
7.4.3.2.1. Sponsors’(Big Pharma) Perspective
7.4.3.2.2. ContractService Providers’ Perspective
7.5. Comparisonof Key Performance Indicators
7.6. ConcludingRemarks
8. COMPETITIVEBENCHMARKING
8.1. ChapterOverview
8.2. Assumptionsand Methodology
8.3. CompetitiveBenchmarking by Region
8.3.1. NorthAmerica, Peer Group I
8.3.2. NorthAmerica, Peer Group II
8.3.3. NorthAmerica, Peer Group III
8.3.4. Europe,Peer Group IV
8.3.5. Europe,Peer Group V
8.3.6. Europe,Peer Group VI
8.3.7. Asia-Pacific,Peer Group VII
8.3.8. Asia-Pacific,Peer Group VIII
8.3.9. RoW,Peer Group IX
8.4. ConcludingRemarks
9. BRANDPOSITIONING OF KEY INDUSTRY PLAYERS
9.1. ChapterOverview
9.2. Scopeand Methodology
9.3. BrandPositioning Matrix: Labcorp
9.4. BrandPositioning Matrix: IQVIA
9.5. BrandPositioning Matrix: Syneos Health
9.6. BrandPositioning Matrix: PPD
9.7. BrandPositioning Matrix: ICON
9.8. BrandPositioning Matrix: Charles River Laboratories
9.9. BrandPositioning Matrix: WuXi AppTec
9.10. BrandPositioning Matrix: Medpace
9.11. BrandPositioning Matrix: PAREXEL International
9.12. BrandPositioning Matrix: NAMSA
10. CLINICALTRIAL ANALYSIS
10.1. ChapterOverview
10.2. Scopeand Methodology
10.3. MedicalDevices: Clinical Trial Analysis
10.3.1. Analysisby Trial Registration Year
10.3.2. Analysisby Trial Status
10.3.3. Analysisby Trial Phase
10.3.4. Analysisby Therapeutic Area
10.3.5. Analysisby Geography
10.3.6. GeographicalAnalysis by Trial Status
10.4. Analysisby Type of Sponsor
10.5. MedicalDevices: Analysis of Enrolled Patient Population
10.5.1. Analysisby Trial Registration Year
10.5.2. Analysisby Trial Status
10.5.3. Analysisby Trial Phase
10.5.4. Analysisby Therapeutic Area
10.5.5. Analysisby Location of Trial Site
10.5.6. Analysisby Trial Status and Location of Trial Site
11. MERGERSAND ACQUISITIONS
11.1. ChapterOverview
11.2. Mergerand Acquisition Models
11.3. Medical Device CROs: Mergersand Acquisitions
11.3.1. Analysis by Year of Merger /Acquisition
